{
  "id": 18914013,
  "title": "Street Calls of The Week",
  "url": "https://urgent.news/2026/11/08/street-calls-of-the-week",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-08T10:05:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/street-calls-of-the-week-93CH-5009979"
  },
  "original_language": "en",
  "account": "Each day below highlights the rating change that accompanied the most significant close-to-close movement. The shifts were gauged based on daily bars (closing price compared to the preceding day's close). Every one of these equities also experienced earnings announcements or news releases on the same day, indicating that the rating alteration served as a co-factor rather than the sole catalyst. Only stocks with a rating adjustment on that particular day were assessed; other calls might have exhibited greater fluctuations. Analysts at Inovio Pharmaceuticals (INO) elevated their rating to Buy following the FDA's endorsement of their inaugural product, INO-3107 (Voceryq). The stock's price surged from $0.6024 to $1.89, representing a staggering +213.7% increase driven by heavy trading volume. The FDA decision emerged as the primary impetus. The research noted that Jefferies upgraded their rating from Hold to Buy, targeting $3.00 (from $1.80), while H.C. Wainwright maintained a Neutral rating at $2.50. Following this, the stock experienced a substantial portion of its initial gain. It closed at $1.215 on Friday, marking a 36% decline from Monday's closing price. Contrasting this trend, Goldman Sachs downgraded Floor & Decor (FND) to Sell, yet the stock experienced a 3.3% rise to $49.14. Goldman Sachs upgraded Ibotta (IBTA) to Neutral from Sell and adjusted its target price to $58 from $35. The stock closed at $60.35 from $50.07, indicating a +20.5% increase. This move followed the company's Q3 results, which Goldman's analysts deemed indicative of the platform transition gaining momentum. Runner-up for the week was a downgrade. Rosenblatt reduced ADTRAN (ADTN) due to telco exposure, resulting in a -19.4% decline in stock price to $5.06. Oppenheimer also downgraded Amdocs (DOX) as the company reported sharply lower fiscal 2027 revenue and profit forecasts, attributing the reduction to a dispute with T-Mobile. The stock fell from $62.43 to $43.66, a -30.1% decrease—representing the steepest single-day drop for the week outside of Friday. The Q4 results, while meeting expectations, were insufficient to offset the impact of the guidance downgrade. BofA downgraded LegalZoom (LZ) due to AI pressures and lowered its target price to $6. As of November 6, 2026, the stock's price had dropped from $6.90 to $5.955, a -13.7% decline. It subsequently experienced an additional 12.1% decrease on Friday, closing at $5.24. Q3 revenue amounted to $195.14 million, slightly surpassing estimates, while adjusted EPS of $0.19 failed to meet the $0.20 forecast, and EBITDA guidance was revised downward. Regarding the remaining Thursday calls, such as Freedom Broker on Black Hills, daily moves did not fall within the scope of measurement. William Blair downgraded NerdWallet (NRDS) to Market Perform. The stock closed at $7.89 on November 6, 2026, reflecting a -31.0% single-day move from its opening price of $11.43. This marked the week's largest individual daily change among the rating calls evaluated. The Q3 shortfall, driven by an EPS of $0.23 against the expected $0.34 and revenue of $239.6 million versus the projected $251.89 million, served as the primary catalyst. On Friday, the most substantial upside moves were observed in Sylvamo (SLVM), Centrus Energy (LEU), and SiTime (SITM). BofA upgraded Sylvamo to Buy on November 3, although the stock's surge did not materialize until Friday. Centrus Energy and SiTime achieved price increases of 17.5% and 17.4%, respectively, following upgrades from Roth/MKM and Seaport. Prices are recorded as daily closing values as of November 6, 2026, at EST. Daily fluctuations are computed as the difference between closing prices and their preceding day's closing value, rather than intraday peaks. This report was crafted with the assistance of AI and subsequently reviewed by an editor. For additional details, please refer to the Terms and Conditions.",
  "summary": null,
  "key_points": [
    "Inovio Pharmaceuticals upgraded to Buy after FDA approval of INO-3107",
    "Floor & Decor downgraded to Sell despite 3.3% price increase",
    "NerdWallet downgraded to Market Perform with 31% single-day drop"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}